Bardoxolone (CDDO) 100mg 100mg | Purity Not Available
Adooq Bioscience
Bardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata’s portfolio of Antioxidant Inflammation Modulators (AIMs).
More Information Supplier PageBardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata’s portfolio of Antioxidant Inflammation Modulators (AIMs).
More Information Supplier PageBardoxolone methyl, previously known as RTA 402, is the lead molecule in Reata’s portfolio of Antioxidant Inflammation Modulators (AIMs).
More Information Supplier PageBardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageBardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageBardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageBardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageBardoxolone methyl is an orally-available first-in-class synthetic triterpenoid. It is an inducer of the Nrf2 pathway, which can suppress oxidative stress and inflammation.
More Information Supplier PageMoxonidine is a new-generation centrally-acting antihypertensive drug. It may have a role when thiazides, beta-blockers, ACE inhibitors and calcium channel blockers are not appropriate or have failed to control blood pressure. In addition, it demonstrates favourable effects on parameters of the insulin resistance syndrome, apparently independent of blood pressure reduction.
More Information Supplier Page